LEMAITRE VASCULAR INC

# Signal Note: Deerfield Initiates LMAT Position Deerfield's $2.1M entry into LeMaitre Vascular suggests confidence in the vascular surgery device market, likely driven by procedural volume recovery post-COVID or recent M&A/pipeline catalysts. LeMaitre's core portfolio spans peripheral vascular disease interventions and vascular access devices—areas benefiting from aging demographics and increasing endovascular procedure adoption. Near-term catalysts to monitor include quarterly procedure volumes, any announced acquisitions, or expanded reimbursement coverage that could drive margin expansion.